

AMENDMENTS TO THE CLAIMS

Please amend this application as described in the Claim Listing, which will replace all prior versions and listings of claims in the above-referenced application.

Claim Listing:

1. (original) A pharmaceutical composition product comprising:
 - a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and;
 - b. an actuator able to produce an aerosol of said solution, wherein the spray pattern ellipticity ratio of said aerosol is between 1.00 and 1.40 when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip.
2. (withdrawn) The Y2 receptor binding compound of claim 1 comprising PYY(3-36).
3. (withdrawn) The aqueous solution of claim 2 wherein said PYY(3-36) is at a concentration of at least 200 ug/mL.
4. (original) The product of claim 1 wherein said actuator produces an ellipticity of between 1.00 and 1.30.
5. (original) The product of claim 1 comprising an aerosol of between 20 and 200 microliters per actuation.
6. (original) The product of claim 3 wherein said ellipticity is between 1.15 and 1.25.
7. (original) A pharmaceutical composition product comprising:
 - a. an aqueous solution of a Y2 receptor binding compound;
 - b. an actuator to produce an aerosol of said solution, wherein the spray pattern major and minor axes of said aerosol are between 10 and 50 mm when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip.

8. (withdrawn, currently amended) The Y2 receptor binding compound of claim [[6]] 7 comprising PYY(3-36).
9. (withdrawn, currently amended) The aqueous solution of claim [[7]] 8 wherein said PYY(3-36) is at a concentration of at least 200 ug/mL.
10. (original) The product of claim 7 comprising an aerosol of between 20 and 200 microliters per actuation.
11. (original) A pharmaceutical composition product comprising:
 - a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and;
 - b. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size.
12. (currently amended) The product of claim [[9]] 11 wherein less than 5% of the droplets are smaller than 10 microns in size.
13. (currently amended) The product of claim [[9]] 11 wherein less than 1% of the droplets are smaller than 10 microns in size.
14. (original) The product of claim 11 comprising an aerosol of between 20 and 200 microliters per actuation.
15. (original) A pharmaceutical composition product comprising:
 - a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and;
 - b. an actuator selected to produce an aerosol of said solution, wherein droplets between 25 and 700 microns are produced.
16. (original) The product of claim 15 comprising an aerosol of between 20 and 200 microliters per actuation.
17. (new) The product of claim 1, wherein the Y2 receptor binding compound comprises PYY(3-36).

18. (new) The product of claim 17, wherein the aqueous solution comprises PYY(3-36) at a concentration of at least 200 ug/mL.
19. (new) The product of claim 7, wherein the Y2 receptor binding compound comprises PYY(3-36).
20. (new) The product of claim 19, wherein the aqueous solution comprises PYY(3-36) at a concentration of at least 200 ug/mL.